Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer

Lauren Folgosa Cooley; Alexander P. Glaser; Joshua J. Meeks

doi:10.1016/j.urolonc.2020.01.019

Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer

Lauren Folgosa Cooley, Alexander P. Glaser, Joshua J. Meeks^*

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

The Cancer Genome Atlas (TCGA) for bladder cancer was published in 2014 with updated annotation of over 400 patients with muscle-invasive bladder cancer (MIBC) in 2017. This tremendous work established the foundation of the genomic landscape of MIBC. The next steps to utilize information from The Cancer Genome Atlas is to (1) identify the causes of mutation, (2) determine the significant differences and sources of heterogeneity, and (3) apply these tools toward patient care. In this review, we discuss the full spectrum of the genomic landscape of MIBC toward the goal of therapeutic application.

Original language	English (US)
Pages (from-to)	279-286
Number of pages	8
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	40
Issue number	7
DOIs	https://doi.org/10.1016/j.urolonc.2020.01.019
State	Published - Jul 2022

Funding

Funding: J.J.M. is supported by Jesse Brown VA Medical Center, Chicago, IL (grant BX003692). J.J.M. are supported by a grant from the John P. Hanson Foundation for Cancer Research (Milwaukee, WI).

Keywords

APOBEC
Bladder cancer
Genomics
Mutation
Mutation signature

ASJC Scopus subject areas

Urology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.urolonc.2020.01.019

Cite this

@article{5049d3fa65d64ba6be6a006113f65898,

title = "Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer",

abstract = "The Cancer Genome Atlas (TCGA) for bladder cancer was published in 2014 with updated annotation of over 400 patients with muscle-invasive bladder cancer (MIBC) in 2017. This tremendous work established the foundation of the genomic landscape of MIBC. The next steps to utilize information from The Cancer Genome Atlas is to (1) identify the causes of mutation, (2) determine the significant differences and sources of heterogeneity, and (3) apply these tools toward patient care. In this review, we discuss the full spectrum of the genomic landscape of MIBC toward the goal of therapeutic application.",

keywords = "APOBEC, Bladder cancer, Genomics, Mutation, Mutation signature",

author = "Cooley, {Lauren Folgosa} and Glaser, {Alexander P.} and Meeks, {Joshua J.}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2022",

month = jul,

doi = "10.1016/j.urolonc.2020.01.019",

language = "English (US)",

volume = "40",

pages = "279--286",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Mutation signatures to Pan-Cancer Atlas

T2 - Investigation of the genomic landscape of muscle-invasive bladder cancer

AU - Cooley, Lauren Folgosa

AU - Glaser, Alexander P.

AU - Meeks, Joshua J.

PY - 2022/7

Y1 - 2022/7

N2 - The Cancer Genome Atlas (TCGA) for bladder cancer was published in 2014 with updated annotation of over 400 patients with muscle-invasive bladder cancer (MIBC) in 2017. This tremendous work established the foundation of the genomic landscape of MIBC. The next steps to utilize information from The Cancer Genome Atlas is to (1) identify the causes of mutation, (2) determine the significant differences and sources of heterogeneity, and (3) apply these tools toward patient care. In this review, we discuss the full spectrum of the genomic landscape of MIBC toward the goal of therapeutic application.

AB - The Cancer Genome Atlas (TCGA) for bladder cancer was published in 2014 with updated annotation of over 400 patients with muscle-invasive bladder cancer (MIBC) in 2017. This tremendous work established the foundation of the genomic landscape of MIBC. The next steps to utilize information from The Cancer Genome Atlas is to (1) identify the causes of mutation, (2) determine the significant differences and sources of heterogeneity, and (3) apply these tools toward patient care. In this review, we discuss the full spectrum of the genomic landscape of MIBC toward the goal of therapeutic application.

KW - APOBEC

KW - Bladder cancer

KW - Genomics

KW - Mutation

KW - Mutation signature

UR - http://www.scopus.com/inward/record.url?scp=85080132049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080132049&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2020.01.019

DO - 10.1016/j.urolonc.2020.01.019

M3 - Review article

C2 - 32122728

AN - SCOPUS:85080132049

SN - 1078-1439

VL - 40

SP - 279

EP - 286

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 7

ER -

Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this